SCHEMBL13664153

SCHEMBL13664153

O=C(/C(Br)=N/Nc1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 3/20 0.48
ALOX12 P18054 1/20 0.48
NPY1R P25929 1/20 0.48
NPY2R P49146 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CES2 O00748 4/20 0.46
CES1 P23141 4/20 0.46
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA9 Q16790 1/20 0.44
RAB9A P51151 4/20 0.42
GAA P10253 4/20 0.42
NPC1 O15118 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115529 0.89 MAPT (0.63) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL4115527 0.89 MAPT (0.63) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL9917542 0.79 MAPT (0.53) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL2556704 0.75 MAPT (0.64) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL2556700 0.75 MAPT (0.64) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL27301538 0.74 CES2 (0.56) MAPTALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL922713 0.74 MAPT (0.81) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL922712 0.74 MAPT (0.81) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL13817618 0.73 GAA (0.44) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL21283604 0.73 POLB (0.51) MAPTALDH1A1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885ALDH1A1 3415/4885SMN1; SMN2 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.